BG60716B1 - Specific binding agents - Google Patents

Specific binding agents Download PDF

Info

Publication number: BG60716B1
Authority: BG; Bulgaria
Prior art keywords: human antibody; ser; tyr; altered; altered human
Prior art date: 1990-09-07

Application number

BG97607A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG97607A (bg

Inventor

Martine E Verhoeyen

Original Assignee

Unilever Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-09-07

Filing date

1993-04-05

Publication date

1996-01-31

1993-04-05 Application filed by Unilever Nv filed Critical Unilever Nv

1994-03-31 Publication of BG97607A publication Critical patent/BG97607A/bg

1996-01-31 Publication of BG60716B1 publication Critical patent/BG60716B1/bg

Links

230000009870 specific binding Effects 0.000 title claims description 22
239000011230 binding agent Substances 0.000 title claims description 19
239000012634 fragment Substances 0.000 claims abstract description 66
206010028980 Neoplasm Diseases 0.000 claims abstract description 15
201000011510 cancer Diseases 0.000 claims abstract description 10
108090000623 proteins and genes Proteins 0.000 claims description 52
239000013604 expression vector Substances 0.000 claims description 21
239000013612 plasmid Substances 0.000 claims description 21
238000000034 method Methods 0.000 claims description 19
241000588724 Escherichia coli Species 0.000 claims description 17
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 17
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 17
102000007298 Mucin-1 Human genes 0.000 claims description 13
108010008707 Mucin-1 Proteins 0.000 claims description 13
108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
150000001413 amino acids Chemical group 0.000 claims description 9
239000003795 chemical substances by application Substances 0.000 claims description 9
102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 7
102000015728 Mucins Human genes 0.000 claims description 5
108010063954 Mucins Proteins 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 5
239000002773 nucleotide Substances 0.000 claims description 5
125000003729 nucleotide group Chemical group 0.000 claims description 5
238000001727 in vivo Methods 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
235000020256 human milk Nutrition 0.000 claims description 3
238000003384 imaging method Methods 0.000 claims description 3
230000005907 cancer growth Effects 0.000 claims description 2
239000000032 diagnostic agent Substances 0.000 claims description 2
229940039227 diagnostic agent Drugs 0.000 claims description 2
210000004251 human milk Anatomy 0.000 claims description 2
DEAGTWNKODHUIY-MRFFXTKBSA-N Ala-Tyr-Trp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DEAGTWNKODHUIY-MRFFXTKBSA-N 0.000 claims 4
UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 claims 4
NEHSHYOUIWBYSA-DCPHZVHLSA-N Phe-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)N NEHSHYOUIWBYSA-DCPHZVHLSA-N 0.000 claims 4
NOFBJKKOPKJDCO-KKXDTOCCSA-N Phe-Ala-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O NOFBJKKOPKJDCO-KKXDTOCCSA-N 0.000 claims 4
GSCVDSBEYVGMJQ-SRVKXCTJSA-N Ser-Tyr-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CO)N)O GSCVDSBEYVGMJQ-SRVKXCTJSA-N 0.000 claims 4
UKBSDLHIKIXJKH-HJGDQZAQSA-N Thr-Arg-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UKBSDLHIKIXJKH-HJGDQZAQSA-N 0.000 claims 4
AVYVKJMBNLPWRX-WFBYXXMGSA-N Trp-Ala-Ser Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 AVYVKJMBNLPWRX-WFBYXXMGSA-N 0.000 claims 4
GULIUBBXCYPDJU-CQDKDKBSSA-N Tyr-Leu-Ala Chemical compound [O-]C(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 GULIUBBXCYPDJU-CQDKDKBSSA-N 0.000 claims 4
AUZADXNWQMBZOO-JYJNAYRXSA-N Tyr-Pro-Arg Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=C(O)C=C1 AUZADXNWQMBZOO-JYJNAYRXSA-N 0.000 claims 4
GPLTZEMVOCZVAV-UFYCRDLUSA-N Tyr-Tyr-Arg Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=C(O)C=C1 GPLTZEMVOCZVAV-UFYCRDLUSA-N 0.000 claims 4
108010069205 aspartyl-phenylalanine Proteins 0.000 claims 4
108010057952 lysyl-phenylalanyl-lysine Proteins 0.000 claims 4
108010035534 tyrosyl-leucyl-alanine Proteins 0.000 claims 4
108010071635 tyrosyl-prolyl-arginine Proteins 0.000 claims 4
OLGCWMNDJTWQAG-GUBZILKMSA-N Asn-Glu-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(N)=O OLGCWMNDJTWQAG-GUBZILKMSA-N 0.000 claims 3
DIBZLYZXTSVGLN-CIUDSAMLSA-N Lys-Ser-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O DIBZLYZXTSVGLN-CIUDSAMLSA-N 0.000 claims 3
AUJWXNGCAQWLEI-KBPBESRZSA-N Phe-Lys-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O AUJWXNGCAQWLEI-KBPBESRZSA-N 0.000 claims 3
WXUBSIDKNMFAGS-IHRRRGAJSA-N Ser-Arg-Tyr Chemical compound NC(N)=NCCC[C@H](NC(=O)[C@H](CO)N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WXUBSIDKNMFAGS-IHRRRGAJSA-N 0.000 claims 3
OOKCGAYXSNJBGQ-ZLUOBGJFSA-N Ser-Asn-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O OOKCGAYXSNJBGQ-ZLUOBGJFSA-N 0.000 claims 3
VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 claims 3
UMSZZGTXGKHTFJ-SRVKXCTJSA-N Tyr-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 UMSZZGTXGKHTFJ-SRVKXCTJSA-N 0.000 claims 3
BWMMKQPATDUYKB-IHRRRGAJSA-N Arg-Tyr-Asn Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 BWMMKQPATDUYKB-IHRRRGAJSA-N 0.000 claims 1
MFNUFCFRAZPJFW-JYJNAYRXSA-N Glu-Lys-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFNUFCFRAZPJFW-JYJNAYRXSA-N 0.000 claims 1
VUBIPAHVHMZHCM-KKUMJFAQSA-N Leu-Tyr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 VUBIPAHVHMZHCM-KKUMJFAQSA-N 0.000 claims 1
RDFQNDHEHVSONI-ZLUOBGJFSA-N Ser-Asn-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDFQNDHEHVSONI-ZLUOBGJFSA-N 0.000 claims 1
XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 claims 1
BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 claims 1
101710172711 Structural protein Proteins 0.000 claims 1
238000002347 injection Methods 0.000 claims 1
239000007924 injection Substances 0.000 claims 1
108010071421 milk fat globule Proteins 0.000 claims 1
230000000295 complement effect Effects 0.000 abstract description 4
238000012546 transfer Methods 0.000 abstract description 2
101001034314 Homo sapiens Lactadherin Proteins 0.000 abstract 1
102100039648 Lactadherin Human genes 0.000 abstract 1
241000699670 Mus sp. Species 0.000 abstract 1
230000001413 cellular effect Effects 0.000 abstract 1
210000000981 epithelium Anatomy 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 18
108091034117 Oligonucleotide Proteins 0.000 description 15
230000027455 binding Effects 0.000 description 14
239000002299 complementary DNA Substances 0.000 description 14
239000013598 vector Substances 0.000 description 14
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 12
125000003275 alpha amino acid group Chemical group 0.000 description 11
239000003623 enhancer Substances 0.000 description 10
241001529936 Murinae Species 0.000 description 8
238000010367 cloning Methods 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
108090000765 processed proteins & peptides Proteins 0.000 description 8
239000000463 material Substances 0.000 description 7
229920001184 polypeptide Polymers 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
239000000872 buffer Substances 0.000 description 6
238000010790 dilution Methods 0.000 description 6
239000012895 dilution Substances 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
108060003951 Immunoglobulin Proteins 0.000 description 5
239000000427 antigen Substances 0.000 description 5
108091007433 antigens Proteins 0.000 description 5
102000036639 antigens Human genes 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
229940098773 bovine serum albumin Drugs 0.000 description 5
230000029087 digestion Effects 0.000 description 5
102000018358 immunoglobulin Human genes 0.000 description 5
238000003780 insertion Methods 0.000 description 5
230000037431 insertion Effects 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
206010006187 Breast cancer Diseases 0.000 description 4
208000026310 Breast neoplasm Diseases 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
206010035226 Plasma cell myeloma Diseases 0.000 description 4
241000283984 Rodentia Species 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
201000000050 myeloid neoplasm Diseases 0.000 description 4
230000037361 pathway Effects 0.000 description 4
239000011049 pearl Substances 0.000 description 4
108091033380 Coding strand Proteins 0.000 description 3
206010061535 Ovarian neoplasm Diseases 0.000 description 3
241001672648 Vieira Species 0.000 description 3
239000011324 bead Substances 0.000 description 3
239000002738 chelating agent Substances 0.000 description 3
238000010586 diagram Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
230000016784 immunoglobulin production Effects 0.000 description 3
230000002611 ovarian Effects 0.000 description 3
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
208000002495 Uterine Neoplasms Diseases 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
238000005406 washing Methods 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
108010032595 Antibody Binding Sites Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108700004676 Bence Jones Proteins 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
108010040156 DNA modification methylase EcoRII Proteins 0.000 description 1
108010031812 DNA modification methylase PstI Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
229910052688 Gadolinium Inorganic materials 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
208000002151 Pleural effusion Diseases 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
RYGMFSIKBFXOCR-IGMARMGPSA-N copper-64 Chemical compound [64Cu] RYGMFSIKBFXOCR-IGMARMGPSA-N 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
101150106093 gpt gene Proteins 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
239000012216 imaging agent Substances 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
229940055742 indium-111 Drugs 0.000 description 1
APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
235000021243 milk fat Nutrition 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
238000010606 normalization Methods 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
238000013492 plasmid preparation Methods 0.000 description 1
229920009537 polybutylene succinate adipate Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000037452 priming Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229910000938 samarium–cobalt magnet Inorganic materials 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000012882 sequential analysis Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000012800 visualization Methods 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pretreatment Of Seeds And Plants (AREA)
Nonmetallic Welding Materials (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

BG97607A 1990-09-07 1993-04-05 Specific binding agents BG60716B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB909019553A GB9019553D0 (en)	1990-09-07	1990-09-07	Specific binding agents
PCT/GB1991/001511 WO1992004380A1 (fr)	1990-09-07	1991-09-05	Agents de liaison specifiques

Publications (2)

Publication Number	Publication Date
BG97607A BG97607A (bg)	1994-03-31
BG60716B1 true BG60716B1 (en)	1996-01-31

Family

ID=10681827

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG97607A BG60716B1 (en)	1990-09-07	1993-04-05	Specific binding agents

Country Status (18)

Country	Link
US (2)	US6204366B1 (fr)
EP (1)	EP0483961B1 (fr)
JP (2)	JP3514456B2 (fr)
KR (1)	KR930702526A (fr)
AT (1)	ATE233279T1 (fr)
AU (1)	AU653167B2 (fr)
BG (1)	BG60716B1 (fr)
CA (1)	CA2090961C (fr)
DE (1)	DE69133200T2 (fr)
DK (1)	DK0483961T3 (fr)
ES (1)	ES2193129T3 (fr)
FI (2)	FI113873B (fr)
GB (1)	GB9019553D0 (fr)
HU (2)	HUT67796A (fr)
NO (2)	NO314595B1 (fr)
RO (1)	RO113432B1 (fr)
UA (1)	UA46691C2 (fr)
WO (1)	WO1992004380A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6800738B1 (en)	1991-06-14	2004-10-05	Genentech, Inc.	Method for making humanized antibodies
WO1994004679A1 (fr) *	1991-06-14	1994-03-03	Genentech, Inc.	Procede pour fabriquer des anticorps humanises
US6407213B1 (en)	1991-06-14	2002-06-18	Genentech, Inc.	Method for making humanized antibodies
JP4157160B2 (ja) *	1991-12-13	2008-09-24	ゾーマテクノロジーリミテッド	改変抗体可変領域の調製のための方法
US5869619A (en) *	1991-12-13	1999-02-09	Xoma Corporation	Modified antibody variable domains
AU5615594A (en) *	1992-11-13	1994-06-08	Cancer Research Fund Of Contra Costa	Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
US6281335B1 (en) *	1993-10-08	2001-08-28	Coulter Corporation	Hybridoma and anti-KC-4 humanized monoclonal antibody
US5804187A (en) *	1992-11-16	1998-09-08	Cancer Research Fund Of Contra Costa	Modified antibodies with human milk fat globule specificity
DE69332930T2 (de) *	1992-11-16	2004-02-26	Cancer Research Fund Of Contra Costa, Walnut Creek	Peptide mit breiter neoplastischer spezifizität
US5792852A (en) *	1992-11-16	1998-08-11	Cancer Research Fund Of Contra Costa	Polynucleotides encoding modified antibodies with human milk fat globule specificity
JPH07203974A (ja) *	1994-01-13	1995-08-08	Tosoh Corp	癌特異的ムチンを認識する抗体の遺伝子断片等
EP0781847A1 (fr) *	1995-11-06	1997-07-02	MERCK PATENT GmbH	Anticorps monoclonal humanisé
JP2002507544A (ja) *	1997-11-14	2002-03-12	ユーロ−セルティーク，エス．エイ．	抗イディオタイプ応答を引き出す能力が増強された改変型の抗体
GB2360771A (en) *	2000-03-28	2001-10-03	Antisoma Res Ltd	Compounds for targeting
WO2001074905A1 (fr) *	2000-04-03	2001-10-11	Antisoma Research Limited	Composes de ciblage
US20040143101A1 (en) *	2001-04-02	2004-07-22	Soltis Daniel A.	Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response
GB0200657D0 (en) *	2002-01-12	2002-02-27	Antisoma Plc	Cancer treatment
JP4753578B2 (ja) *	2002-06-03	2011-08-24	ジェネンテック，インコーポレイテッド	合成抗体ファージライブラリー
US20040059093A1 (en) *	2002-07-16	2004-03-25	Stuart Bussell	Methods to construct multimeric DNA and polymeric protein sequences as direct fusions or with linkers
WO2005012531A2 (fr) *	2003-08-01	2005-02-10	Genentech, Inc.	Polypeptides de liaison avec sequences de diversite restreinte
GB0519398D0 (en) *	2005-09-23	2005-11-02	Antisoma Plc	Biological materials and uses thereof
WO2007056441A2 (fr)	2005-11-07	2007-05-18	Genentech, Inc.	Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
WO2007064919A2 (fr) *	2005-12-02	2007-06-07	Genentech, Inc.	Polypeptides de liaison avec des sequences de diversite limitees
WO2012051111A2 (fr) *	2010-10-13	2012-04-19	Janssen Biotech, Inc.	Anticorps contre l'oncostatine m humaine et procédés d'utilisation
JP2014510080A (ja) *	2011-03-09	2014-04-24	セントローズ，エルエルシー	細胞外標的化薬物複合体
RU2493165C1 (ru) *	2012-02-28	2013-09-20	Общество с ограниченной ответственностью "Технофарма"	Наноантитело, специфически связывающее белок muc1, способ детекции белка muc1 с помощью наноантител
RU2018102251A (ru)	2012-04-30	2019-02-21	Байотера, Инк.	СПОСОБЫ β-ГЛЮКАНОВОЙ ИММУНОТЕРАПИИ

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8607679D0 (en) *	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
WO1988005054A1 (fr) *	1987-01-07	1988-07-14	Imperial Cancer Research Technology Limited	Sonde
AU612370B2 (en) *	1987-05-21	1991-07-11	Micromet Ag	Targeted multifunctional proteins
AU3049189A (en) *	1988-02-08	1989-08-25	John Muir Cancer & Aging Institute	Monoclonal antibody specific to a novel mucin-like glycoprotein surface antigen on human carcinoma cells
JPH04501719A (ja) *	1988-11-10	1992-03-26	インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド	ポリペプチド
EP0369816A3 (fr) *	1988-11-17	1990-09-12	The University Of Melbourne	Anticorps monoclonaux spécifiques pour la mucine polymorphe épithéliale humaine
US5075219A (en) *	1989-04-05	1991-12-24	John Muir Cancer & Aging Institute	Monoclonal antibody which recognizes a specific glycoprotein of a human milk-fat globule membrane mucin antigen and said mucin antigen
RO110262B1 (ro) *	1989-11-17	1995-11-30	Unilever Nv	Anticorp uman, reformat si gena care il codifica

1990
- 1990-09-07 GB GB909019553A patent/GB9019553D0/en active Pending
1991
- 1991-09-05 AT AT91308147T patent/ATE233279T1/de not_active IP Right Cessation
- 1991-09-05 RO RO93-00310A patent/RO113432B1/ro unknown
- 1991-09-05 CA CA002090961A patent/CA2090961C/fr not_active Expired - Lifetime
- 1991-09-05 EP EP91308147A patent/EP0483961B1/fr not_active Expired - Lifetime
- 1991-09-05 JP JP51496191A patent/JP3514456B2/ja not_active Expired - Lifetime
- 1991-09-05 AU AU84953/91A patent/AU653167B2/en not_active Expired
- 1991-09-05 UA UA93080844A patent/UA46691C2/uk unknown
- 1991-09-05 WO PCT/GB1991/001511 patent/WO1992004380A1/fr active IP Right Grant
- 1991-09-05 KR KR1019930700678A patent/KR930702526A/ko not_active Ceased
- 1991-09-05 DK DK91308147T patent/DK0483961T3/da active
- 1991-09-05 HU HU9300609A patent/HUT67796A/hu unknown
- 1991-09-05 DE DE69133200T patent/DE69133200T2/de not_active Expired - Lifetime
- 1991-09-05 ES ES91308147T patent/ES2193129T3/es not_active Expired - Lifetime
- 1991-09-05 HU HU9300609A patent/HU9300609D0/hu unknown
- 1991-09-05 US US07/987,264 patent/US6204366B1/en not_active Expired - Lifetime
1993
- 1993-03-05 FI FI930984A patent/FI113873B/fi not_active IP Right Cessation
- 1993-03-05 NO NO19930825A patent/NO314595B1/no not_active IP Right Cessation
- 1993-04-05 BG BG97607A patent/BG60716B1/bg unknown
2000
- 2000-12-28 US US09/749,831 patent/US20020086978A1/en not_active Abandoned
2001
- 2001-08-31 FI FI20011739A patent/FI114611B/fi not_active IP Right Cessation
- 2001-10-04 NO NO20014822A patent/NO315239B1/no not_active IP Right Cessation
2002
- 2002-05-30 JP JP2002157535A patent/JP2003061689A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JPH06500468A (ja)	1994-01-20
BG97607A (bg)	1994-03-31
FI113873B (fi)	2004-06-30
US6204366B1 (en)	2001-03-20
RO113432B1 (ro)	1998-07-30
NO20014822D0 (no)	2001-10-04
HUT67796A (en)	1995-04-28
JP2003061689A (ja)	2003-03-04
FI930984A0 (fi)	1993-03-05
KR930702526A (ko)	1993-09-09
ATE233279T1 (de)	2003-03-15
NO314595B1 (no)	2003-04-14
GB9019553D0 (en)	1990-10-24
NO930825D0 (no)	1993-03-05
CA2090961A1 (fr)	1992-03-08
US20020086978A1 (en)	2002-07-04
WO1992004380A1 (fr)	1992-03-19
JP3514456B2 (ja)	2004-03-31
NO20014822L (no)	1993-05-05
HU9300609D0 (en)	1993-05-28
AU653167B2 (en)	1994-09-22
DE69133200T2 (de)	2003-11-20
AU8495391A (en)	1992-03-30
DK0483961T3 (da)	2003-06-23
EP0483961A1 (fr)	1992-05-06
FI930984L (fi)	1993-03-05
UA46691C2 (uk)	2002-06-17
DE69133200D1 (de)	2003-04-03
FI114611B (fi)	2004-11-30
NO315239B1 (no)	2003-08-04
CA2090961C (fr)	2004-01-20
NO930825L (no)	1993-05-05
ES2193129T3 (es)	2003-11-01
EP0483961B1 (fr)	2003-02-26

Publication	Publication Date	Title
BG60716B1 (en)	1996-01-31	Specific binding agents
RU2112037C1 (ru)	1998-05-27	Гибридное моноклональное антитело, взаимодействующее с cd4-антигеном т-хелперных клеток человека, и способ его получения
US5891996A (en)	1999-04-06	Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use
US5712120A (en)	1998-01-27	Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains, compositions containing them
KR100516133B1 (ko)	2005-09-21	항-인간항원 수용체의 신규한 제조방법 및 용도
JPH06506927A (ja)	1994-08-04	Ｐｅｍムチン縦列繰り返し配列特異性単クローン抗体の最小識別単位
CA2087095A1 (fr)	1992-01-26	Domaines associatifs
CN112480250B (zh)	2022-03-15	一种抗人骨桥蛋白的抗体及其应用
KR970007782B1 (ko)	1997-05-16	특이적 결합제
CA2080260C (fr)	2002-12-17	Anticorps monoclonaux contre des antigenes associes aux tumeurs, procedes de preparation et utilisation de ceux-ci
JP2024534706A (ja)	2024-09-20	二重特異性抗体及びその使用
RU2102479C1 (ru)	1998-01-20	Химерное моноклональное антитело, взаимодействующее с человеческой плацентарной щелочной фосфатазой, вариабельная область тяжелой гамма-цепи химерного моноклонального антитела, вариабельная область легкой k-цепи химерного моноклонального антитела, фрагмент кднк, кодирующий вариабельную область тяжелой гамма-цепи химерного моноклонального антитела и фрагмент кднк, кодирующий вариабельную область легкой k-цепи химерного моноклонального антитела
JPH09278799A (ja)	1997-10-28	抗エメリン抗体及び該抗体を用いたエメリンの測定方法